vs
Side-by-side financial comparison of Insulet Corporation (PODD) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $699.9M, roughly 1.1× QuidelOrtho Corp). Insulet Corporation runs the higher net margin — 13.0% vs -104.7%, a 117.7% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -3.7%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-94.7M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -2.9%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
PODD vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $699.9M |
| Net Profit | $101.6M | $-733.0M |
| Gross Margin | 72.6% | — |
| Operating Margin | 18.7% | -100.7% |
| Net Margin | 13.0% | -104.7% |
| Revenue YoY | 31.2% | -3.7% |
| Net Profit YoY | 0.9% | -3583.4% |
| EPS (diluted) | $1.42 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $783.7M | — | ||
| Q3 25 | $706.3M | $699.9M | ||
| Q2 25 | $649.1M | $613.9M | ||
| Q1 25 | $569.0M | $692.8M | ||
| Q4 24 | $597.5M | $707.8M | ||
| Q3 24 | $543.9M | $727.1M | ||
| Q2 24 | $488.5M | $637.0M | ||
| Q1 24 | $441.7M | $711.0M |
| Q4 25 | $101.6M | — | ||
| Q3 25 | $87.6M | $-733.0M | ||
| Q2 25 | $22.5M | $-255.4M | ||
| Q1 25 | $35.4M | $-12.7M | ||
| Q4 24 | $100.7M | $-178.4M | ||
| Q3 24 | $77.5M | $-19.9M | ||
| Q2 24 | $188.6M | $-147.7M | ||
| Q1 24 | $51.5M | $-1.7B |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — | ||
| Q1 24 | 69.5% | — |
| Q4 25 | 18.7% | — | ||
| Q3 25 | 16.7% | -100.7% | ||
| Q2 25 | 18.7% | -29.4% | ||
| Q1 25 | 15.6% | 4.7% | ||
| Q4 24 | 18.3% | -14.2% | ||
| Q3 24 | 16.2% | 2.1% | ||
| Q2 24 | 11.2% | -18.4% | ||
| Q1 24 | 12.9% | -247.3% |
| Q4 25 | 13.0% | — | ||
| Q3 25 | 12.4% | -104.7% | ||
| Q2 25 | 3.5% | -41.6% | ||
| Q1 25 | 6.2% | -1.8% | ||
| Q4 24 | 16.9% | -25.2% | ||
| Q3 24 | 14.2% | -2.7% | ||
| Q2 24 | 38.6% | -23.2% | ||
| Q1 24 | 11.7% | -239.9% |
| Q4 25 | $1.42 | — | ||
| Q3 25 | $1.24 | $-10.78 | ||
| Q2 25 | $0.32 | $-3.77 | ||
| Q1 25 | $0.50 | $-0.19 | ||
| Q4 24 | $1.38 | $-2.54 | ||
| Q3 24 | $1.08 | $-0.30 | ||
| Q2 24 | $2.59 | $-2.20 | ||
| Q1 24 | $0.73 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $98.1M |
| Total DebtLower is stronger | $930.8M | $2.5B |
| Stockholders' EquityBook value | $1.5B | $2.0B |
| Total Assets | $3.2B | $5.7B |
| Debt / EquityLower = less leverage | 0.61× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | $2.5B | ||
| Q2 25 | $939.0M | $2.1B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | $1.4B | $2.2B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.5B | $2.8B | ||
| Q1 25 | $1.3B | $3.0B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $1.1B | $3.2B | ||
| Q2 24 | $998.4M | $3.2B | ||
| Q1 24 | $790.7M | $3.3B |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.0B | $5.7B | ||
| Q2 25 | $3.5B | $6.4B | ||
| Q1 25 | $3.5B | $6.5B | ||
| Q4 24 | $3.1B | $6.4B | ||
| Q3 24 | $3.0B | $6.8B | ||
| Q2 24 | $2.9B | $6.7B | ||
| Q1 24 | $2.6B | $6.7B |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | 1.23× | ||
| Q2 25 | 0.64× | 0.74× | ||
| Q1 25 | 1.21× | 0.70× | ||
| Q4 24 | 1.07× | 0.72× | ||
| Q3 24 | 1.21× | 0.68× | ||
| Q2 24 | 1.36× | 0.70× | ||
| Q1 24 | 1.72× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $-45.5M |
| Free Cash FlowOCF − Capex | $48.2M | $-94.7M |
| FCF MarginFCF / Revenue | 6.2% | -13.5% |
| Capex IntensityCapex / Revenue | 17.2% | 7.0% |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.3M | — | ||
| Q3 25 | $125.7M | $-45.5M | ||
| Q2 25 | $196.5M | $-46.8M | ||
| Q1 25 | $63.8M | $65.6M | ||
| Q4 24 | $147.7M | $63.7M | ||
| Q3 24 | $98.5M | $117.9M | ||
| Q2 24 | $96.5M | $-97.9M | ||
| Q1 24 | $87.6M | $-700.0K |
| Q4 25 | $48.2M | — | ||
| Q3 25 | $100.1M | $-94.7M | ||
| Q2 25 | $177.9M | $-84.3M | ||
| Q1 25 | $51.5M | $9.4M | ||
| Q4 24 | $94.1M | $16.5M | ||
| Q3 24 | $71.8M | $71.4M | ||
| Q2 24 | $74.0M | $-133.2M | ||
| Q1 24 | $65.5M | $-66.8M |
| Q4 25 | 6.2% | — | ||
| Q3 25 | 14.2% | -13.5% | ||
| Q2 25 | 27.4% | -13.7% | ||
| Q1 25 | 9.1% | 1.4% | ||
| Q4 24 | 15.7% | 2.3% | ||
| Q3 24 | 13.2% | 9.8% | ||
| Q2 24 | 15.1% | -20.9% | ||
| Q1 24 | 14.8% | -9.4% |
| Q4 25 | 17.2% | — | ||
| Q3 25 | 3.6% | 7.0% | ||
| Q2 25 | 2.9% | 6.1% | ||
| Q1 25 | 2.2% | 8.1% | ||
| Q4 24 | 9.0% | 6.7% | ||
| Q3 24 | 4.9% | 6.4% | ||
| Q2 24 | 4.6% | 5.5% | ||
| Q1 24 | 5.0% | 9.3% |
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 8.73× | — | ||
| Q1 25 | 1.80× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
